-
Mashup Score: 2
Patients with relapsed/refractory multiple myeloma (RRMM) need proven subsequent therapies after early-line lenalidomide treatment failure. The phase 2 MM-014 trial (NCT01946477) investigated pomalidomide, dexamethasone, and daratumumab after 1 to 2 prior treatment lines (62.5%, 1 prior line) in pat …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Oncopeptides AB.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day (1/2): Phase 3 OCEAN study comparing #Pepaxto/dex to or #Pomalyst/dex for patients with #myeloma refractory to #Revlimid shows better PFS but significantly worse OS (19.8 months vs. 25.0 months): https://t.co/d5wN4SsYsl. Please see 2/2 on this paper. https://t.co/vNXczuyUNW
-
-
Mashup Score: 1Safety and Efficacy of Combination Maintenance Therapy with Ixazomib and Lenalidomide in Post-transplant Myeloma Patients - PubMed - 2 year(s) ago
The addition of ixazomib to lenalidomide maintenance demonstrated a better than expected PFS compared with historical data using lenalidomide alone and was safe and tolerable.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: @MDAndersonNews study of safety & efficacy of maintenance with #Ninlaro and #Revlimid in post-transplant #myeloma patients finds deepening response rates & median PFS of 73 months: https://t.co/growVh0OSx. https://t.co/QSKmaU1IlG
-
-
Mashup Score: 0
In the phase 3 MAIA study of patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab plus lenalidomide/dexamethasone (D-Rd) improved progression-free survival (PFS) versus lenalidomide/dexamethasone (Rd). We present a subgroup analysis of MAIA by frailty status. Frai …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: MAIA substudy shows #Darzalex plus #Revlimid and dex in transplant-ineligible newly diagnosed frail #myelomapatients maintains superiority to #Revlimid /dex in PFS & MRD-negativity: https://t.co/YJIQnrjALv https://t.co/lFpv8N3Fao
-
-
Mashup Score: 0
For the Italian translation of the abstract see Supplementary Materials section.
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: FORTE trial of #Kyprolis/#Cytoxan/dex vs. #Kyprolis/#Revlimid/dex (KRd) vs. KRd + ASCT finds KRd + ASCT was the best arm, and KR maintenance was better than R alone: https://t.co/9u1H90srT2. https://t.co/slXXSdU1A4
-
-
Mashup Score: 1Multiple Myeloma Clinical Trials - 3 year(s) ago
FORTE Trial Data Published NCT02203643: Phase 2 – Carf/Cyclo./Dex Vs Carf/Len/Dex -> ASCT or 12 Cy Carf/Len/Dex – NDMM – FORTE Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with…
Source: Myeloma TrialsCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @afshanmalikmd: https://t.co/kfYF3BQbT9 NCT02203643: Phase 2 - #FORTE trial #Kyprolis #Revlimid #Dexamethasone KRd plus #ASCT showed sup…
-
-
Mashup Score: 0MCT1 is a Predictive Marker for Lenalidomide Maintenance Therapy in Multiple Myeloma - PubMed - 3 year(s) ago
Biomarkers that predict response to lenalidomide maintenance therapy in patients with multiple myeloma (MM) have remained elusive. We have shown that IMiDs exert anti-MM activity via destabilization of MCT1 and CD147. Here, samples of 654 patients receiving lenalidomide (n=455), thalidomide (n=98) o …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: MCT1 may be a predictive marker for #Revlimid maintenance therapy in #myeloma patients, with high expression levels being associated with inferior PFS and OS: https://t.co/ui9BXD3YCE. https://t.co/mY66KsBvwo
-
-
Mashup Score: 6Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance - PubMed - 3 year(s) ago
Standard-of-care for newly-diagnosed, autologous hematopoietic stem cell transplantation (auto-HCT)-eligible, multiple myeloma (MM) patients includes bortezomib, lenalidomide, and dexamethasone (VRD) induction followed by melphalan 200 mg/m2 (Mel200)-conditioned auto-HCT and lenalidomide …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: @MDAndersonNews study of real-world long-term outcomes in #myeloma with VRD induction, Mel200-auto-HCT, & #Revlimid maintenance finds median follow-up, PFS, OS were 63.2, 50, 101.7 months, respectively: https://t.co/rHP4z6e1v8. @Transplant_Doc https://t.co/OwVk9SoMGk
-
-
Mashup Score: 2
MM-GVAX, along with lenalidomide, effectively primed durable immunity and resulted long-term disease control, as suggested by the reappearance of a detectable, fluctuating M-spike without meeting the criteria for clinical relapse. For patients in a nCR, MM-GVAX administration was safe and resulted i …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: An allogeneic multiple #myeloma GM-CSF-secreting vaccine with #Revlimid induces long-term immunity and durable clinical responses in patients in near complete remission: https://t.co/2b1k0sq53u. https://t.co/U9LKjmRdXm
-
-
Mashup Score: 7The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM) - PubMed - 3 year(s) ago
The optimal duration of lenalidomide maintenance post-autologous stem cell transplant (ASCT) in Multiple Myeloma (MM), and choice of therapy at relapse post-maintenance, need further evaluation. This retrospective study assessed outcomes of patients with MM (n = 213) seen at Mayo Clinic, Rochester b …
Source: PubMedCategories: Hem/Oncs, Latest HeadlinesTweet-
#Myeloma Paper of the Day: Study of the effect of duration of #Revlimid maintenance and outcomes of different salvage regimens in #myeloma finds patients with ≥3 years of maintenance had a superior 5-year OS: https://t.co/7mAJC7blcx. https://t.co/Ks8K1lQqNH
-
#Myeloma Paper of the Day: Phase II study of#Pomalyst/#Darzalex/dex given immediately after #Revlimid-based treatment in patients with #myeloma finds 77.7% response rate & median PFS of 30.8 months: https://t.co/jzPpAxDpgT. https://t.co/ThBFbkdI8W